IFNAR

DMXAA (ASA404) is a tumor-vascular disrupting agent (tumor-VDA) that attacks the blood supply of a cancerous tumor to cause tumor regression.

2',3'-cGAMP (2'-3'-cyclic GMP-AMP) is a endogenous cGAMP in mammalian cells.

AX-024 is an cytokine release inhibitor which can strongly inhibit the production of interleukin-6 (IL-6), tumor necrosis factor-α (TNFα), interferon-γ (IFN-γ), IL-10 and IL-17A.

AX-024 is an orally available inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation (IC50 value 1 nM). Inhibiting an immediate TCR signal has promise for treating a broad spectrum of human T cell-mediated autoimmune and inflammatory diseases.

CCCP is an oxidative phosphorylation uncoupler. CCCP induces activation of PINK1 leading to Parkin Ser65 phosphorylation.

IFN alpha-IFNAR-IN-1 hydrochloride is a nonpeptidic, low-molecular-weight inhibitor of the interaction between IFN-α and IFNAR; inhibit MVA-induced IFN-α responses by BM-pDCs (IC50=2-8 uM).

Icotrokinra (JNJ-77242113) is an orally available and selective antagonist of the interleukin-23 (IL-23) receptor. It potently inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC₅₀ = 5.6 pM) and suppresses IL-23-induced interferon-γ (IFN-γ) production in natural killer (NK) cells (IC₅₀ = 18.4 pM). Icotrokinra also demonstrates anti-inflammatory activity in a rat TNBS-induced colitis model. It is a promising therapeutic candidate for the study and treatment of inflammatory conditions such as psoriasis, psoriatic arthritis, and inflammatory bowel disease (IBD).

RIG012 is a potent inhibitor of RIG-I with an IC50 of 0.71 μM, as determined by the NADH-coupled ATPase assay. It effectively suppresses the expression of interferon beta (IFN-β) and the interferon-stimulated gene hRsad2. RIG012 is valuable for research applications focusing on the modulation of innate immune responses and the study of viral infections.

YE6144 is a selective interferon regulatory factor 5 (IRF5) inhibitor. It exhibits significant biological activity by suppressing disease progression and is particularly effective for maintaining remission in murine models of systemic lupus erythematosus (SLE). This compound serves as a valuable tool for researchers investigating the mechanisms of SLE and the role of IRF5 in autoimmune diseases.

IFN-γ Antagonist 1 (AYCRDGKIGPPKLDIRKEEKQI) functions as an antagonist of interferon-γ (IFN-γ). This compound effectively inhibits IFN-γ-induced HLR/DR antigen expression in cellular models. Its application is particularly relevant in the investigation of diseases characterized by dysregulation of immune responses.

2'-Deoxy-2'-fluorouridine is a nucleoside analog targeting viral replication. It effectively inhibits the replication of wild-type viruses by binding to viral RNA, while also demonstrating capacity to incorporate into DNA and RNA in vivo models. Furthermore, this compound can be utilized as a precursor in the development of respiratory syncytial virus (RSV) polymerase inhibitors. Its unique mechanism makes 2'-Deoxy-2'-fluorouridine a valuable compound for antiviral research applications.

Z36-MP5 is a targeted inhibitor of Mi-2β, exhibiting an IC50 value of 0.082 μM. This compound effectively reduces Mi-2β ATPase activity, leading to the reactivation of interferon-stimulated gene (ISG) transcription. Additionally, Z36-MP5 is known to enhance T-cell-mediated cytotoxicity, making it a valuable tool for research in immunology and potential therapeutic applications in cancer and viral infections.

CP-20961 is a synthetic non-immunogenic adjuvant with the primary mechanism of inducing interferon production. This compound has been shown to effectively enhance immune responses and modulate inflammation, making it relevant for studying autoimmune conditions such as arthritis. Its application as an adjuvant in therapeutic and vaccine research holds promise for advancing understanding of immune modulation and disease management.

IFNα-IN-1 is an SLC5A4 inhibitor that specifically targets and inhibits the production of interferon-alpha (IFN-α). Its primary biological activity is to modulate the inflammatory response by reducing IFN-α levels. This reagent is suitable for research applications focused on studying inflammation and related disease mechanisms.

VISTA-IN-3 is a potent small molecule inhibitor of the VISTA pathway, exhibiting a KD value of 0.49 μM. It effectively induces the release of IFN-γ cytokines, thereby enhancing immune responses. Additionally, VISTA-IN-3 demonstrates synergistic effects when combined with PD-L1 antibodies, making it a valuable tool for cancer immunotherapy research.

ODN D-SL03 is a C class CpG oligonucleotide that primarily targets immune cells to induce the production of high levels of interferon-alpha (IFN-α) in peripheral blood mononuclear cells (PBMCs). It effectively activates human B cells, natural killer (NK) cells, and mononuclear cells while enhancing the expression of costimulatory molecules CD80, CD86, and HLA-DR on various PBMC subsets. Additionally, ODN D-SL03 exhibits tumor-inhibiting properties, making it valuable for research in immunotherapy and cancer treatment. Sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3'.

ODN 6016 is a CpG-A oligonucleotide that acts as a potent immunostimulatory agent through the induction of interferon alpha (IFN-α) production. This compound is valuable for investigating immune disorders, particularly those related to immunodeficiency mechanisms associated with HIV-1. The specific sequence of ODN 6016 is T-sp-C-G-A-C-G-T-C-G-T-G-G-sp-G-sp-G-sp-G, enabling targeted research applications in the field of immunology.

Frenlosirsen sodium is an antisense oligonucleotide that specifically targets IRF4, a critical regulator in immune responses. This compound has demonstrated potential in the study of relapsed or refractory multiple myeloma (RRMM), facilitating research into therapeutic interventions for this challenging malignancy. Its mechanisms may provide insight into the modulation of immune pathways associated with multiple myeloma progression and treatment resistance.

Frenlosirsen is an antisense oligonucleotide that specifically targets interferon regulatory factor 4 (IRF4). It is utilized in research focused on relapsed or refractory multiple myeloma (RRMM), enabling the examination of therapeutic strategies aimed at modulating this transcription factor. This reagent serves as a valuable tool for understanding the role of IRF4 in tumorigenesis and resistance mechanisms in hematological malignancies.

IFN alpha-IFNAR-IN-1 is a small-molecule inhibitor that specifically targets the interaction between interferon-alpha (IFN-α) and its receptor, IFNAR. This compound effectively inhibits IFN-α responses induced by modified Vaccinia virus Ankara (MVA) in murine bone marrow-derived plasmacytoid dendritic cell (pDC) cultures, exhibiting an IC50 of 2-8 μM. It serves as a valuable tool for studying the immune response modulation in various infectious and inflammatory conditions.

2'2'-cGAMP is a synthetic cyclic dinucleotide (CDN) that targets the STING (Stimulator of Interferon Genes) pathway, playing a crucial role in the immune response. It effectively induces the production of interferon-beta (IFN-β), a key cytokine involved in antiviral defense. While 2'2'-cGAMP exhibits a weaker affinity for STING compared to 2'3'-cGAMP, it demonstrates a stronger interaction than other CDNs, making it valuable for research in immunology and therapeutic applications related to immune modulation.

Bifarcept is an interferon receptor type I (IFN-RI) fusion protein that functions by binding to interferon receptors, thereby extending their serum half-life. This enhancement can facilitate prolonged biological activity and efficacy in therapeutic applications. Bifarcept is primarily utilized in research exploring the immune response and potential treatments for various diseases mediated by interferon signaling.

StA-IFN-1 is a selective inhibitor of type I interferon (IFN), specifically targeting the activation of IFNβ with an IC50 of 4.1 μM. This compound is utilized in research exploring the roles of IFNβ in immune responses and associated pathologies. Its inhibitory properties make it a valuable reagent for studying the modulation of inflammatory processes and therapeutic strategies in various disease models.

YE6144 free base is a selective inhibitor of interferon regulatory factor 5 (IRF5). It effectively suppresses disease progression and is particularly beneficial for maintaining remission in preclinical models of systemic lupus erythematosus (SLE). This compound serves as a valuable tool for researchers investigating the role of IRF5 in autoimmune disorders and potential therapeutic strategies for SLE.

Sim-9 is a covalent allosteric inhibitor targeting interferon regulatory factor 3 (IRF3). By binding covalently to the Cys222 residue, Sim-9 induces a conformational change that inhibits interactions between IRF3 and key signaling partners such as TRIF, MAVS, and STING, ultimately blocking homodimerization and the type I interferon response. This compound demonstrates significant anti-inflammatory and organ-protective effects in mouse models of sepsis and acute pancreatitis, making it a valuable tool for research focused on inflammatory diseases.

Antitumor agent-210 is an NK cell activator known for enhancing the activation and degranulation of natural killer (NK) cells. It exerts a modest proliferative effect on NK92 cells, significantly increasing their cytotoxicity against tumor cells. This compound promotes the release of key cytokines, including granzyme B, perforin, and IFN-γ, and has demonstrated efficacy in reducing lung metastatic lesions in murine models. Antitumor agent-210 is a valuable reagent for researching melanoma lung metastasis and other cancer-related immunological studies.

CP-28888 is an interferon alpha/beta receptor (IFNAR) inducer that enhances the immune response by promoting the production of type I interferons. It exhibits greater potency in murine models, making it a valuable tool for studying immune modulation and antiviral responses in preclinical research. Despite its limited efficacy in human trials and lack of antirhinovirus activity, CP-28888 remains a relevant compound in the investigation of therapeutic approaches targeting interferon pathways.

Ezurpimtrostat (hydrochloride) is a potent and selective PPT1 inhibitor with multiple biological activities. It disrupts lysosomal function, modulates autophagy, and induces apoptosis, making it a valuable tool in cancer research and immunology. This compound has demonstrated efficacy in reducing inflammatory markers such as IFN-α and CRP, as well as in lowering viral loads of SARS-CoV-2. Ezurpimtrostat is suitable for investigating conditions such as systemic lupus erythematosus, hepatocellular carcinoma, fibrosis, and other related disorders.